Evaluation of Caspofungin and Amphotericin B Deoxycholate against Candida albicans Biofilms in an Experimental Intravascular Catheter Infection Model
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Candida albicans biofilms complicate the treatment of infected implanted intravascular devices because of decreased antifungal susceptibility. In our investigation, 48 rabbits with experimental central venous catheter C. albicans infection were equally allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing systemic and intraluminal lock therapy for 7 days. C. albicans was cultured from catheters from all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin. Differences in colony counts were detected between the control and amphotericin (P<.001) and control and caspofungin (P<.001) arms. Caspofungin may be useful in the treatment of C. albicans biofilm-associated intravascular catheter infections, which warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the management of intravascular catheter-related infections
Mermel, L. A., Farr, B. M., Sherertz, R. J., Raad, I. I., O'Grady, N., Harris, J. S., & Craven, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320001 · Cited by 1,449
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880 · cited 1×
“Candida species are often associated with nosocomial bloodstream infections in patients with central venous catheters or other implanted devices [2, 3]; effective medical therapy of these biofilm-associated or-”
BackgroundBiofilm formation by Candida species on the surface of catheter materials in vitro
Hawser, S. P., & Douglas, L. J. (1994) · Infection and Immunity · doi:10.1128/iai.62.3.915-921.1994 · Cited by 599 · cited 1×
“Mature biofilms were formed as described elsewhere [7, 8] for evaluation by scanning electron microscopy (SEM).”
MethodIn Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Cited by
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“If central venous catheter cannot be removed, treatment should include an echinocandin or a lipid formulation of amphotericin B due to their better activity on Candida biofilms.(35-37)”
BackgroundDevelopment and regulation of single- and multi-species Candida albicans biofilms
Lohse, M. B., Gulati, M., Johnson, A. D., & Nobile, C. J. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.107 · Cited by 643
Our Current Understanding of Fungal Biofilms
Ramage, G., Mowat, E., Jones, B., Williams, C., & Lopez-Ribot, J. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903241436 · Cited by 483
Pathogenesis of Candida albicans biofilm
Tsui, C., Kong, E. F., & Jabra-Rizk, M. A. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw018 · Cited by 481
In vitro and in vivo model systems to study microbial biofilm formation
Coenye, T., & Nelis, H. J. (2010) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2010.08.018 · Cited by 463
Bacterial and Fungal Biofilm Infections
Lynch, A. S., & Robertson, G. T. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.110106.132000 · Cited by 447
Candida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
Reactive Oxygen Species-Inducing Antifungal Agents and Their Activity Against Fungal Biofilms
Delattin, N., Cammue, B. P., & Thevissen, K. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.189 · Cited by 189
Vediyappan, G., Rossignol, T., & d'Enfert, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01638-09 · Cited by 183
“Moreover, the extent of the transcriptional response of biofilms to antifungals appeared well correlated to the efficacy of these antifungals toward biofilms, with caspofungin eliciting higher transcriptome alterations than amphotericin B and amphotericin B eliciting higher transcriptome alterations than fluconazole (…”
BackgroundAntifungal therapy with an emphasis on biofilms
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.008 · Cited by 173
Walraven, C. J., & Lee, S. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01351-12 · Cited by 132
The role of antifungals against Candida biofilm in catheter-related candidemia
Bouza, E., Guinea, J., & Guembe, M. (2014) · Antibiotics · doi:10.3390/antibiotics4010001 · Cited by 62
“albicans biofilms [95].”
Kawai, A., Yamagishi, Y., & Mikamo, H. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.05.007 · Cited by 23
Metadata
- Authors
- Shuford, J. A., Rouse, M. S., Piper, K. E., Steckelberg, J. M., & Patel, R.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09
- Volume
- 194
- Issue
- 5
- Pages
- 710-713
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2140612568
- Cited by
- 99
- References
- 5
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.